Teva Pharmaceutical Industries Ltd. (TEVA)

15.02
0.11 0.74
NYSE : Health Technology
Prev Close 14.91
Open 15.05
Day Low/High 14.85 / 15.13
52 Wk Low/High 14.59 / 25.96
Volume 1.58M
Avg Volume 10.46M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 15.88B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva Signs New $2.3 Billion Syndicated Revolving Credit Facility

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has entered into a new $2.

Teva To Host Conference Call To Discuss First Quarter 2019 Financial Results At 8 A.m. ET On May 2, 2019

Teva To Host Conference Call To Discuss First Quarter 2019 Financial Results At 8 A.m. ET On May 2, 2019

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter 2019 financial results on Thursday, May 2, 2019 at 7:00 a.

Weekly Roundup

Markets pushed higher as we gear up for first-quarter results starting next week.

AJOVY Capshot (Graphic: Business Wire)

AJOVY Capshot (Graphic: Business Wire)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the European Commission (EC) has granted the Marketing Authorization for AJOVY (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of...

Teva's COPAXONE® 40mg - Favorable Response From European Patent Office

Teva's COPAXONE® 40mg - Favorable Response From European Patent Office

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office's (EPO) Opposition Division upheld patent EP 2 949 335 covering Teva's COPAXONE ® 40mg product in Europe.

More Mud on Johnson & Johnson?

More Mud on Johnson & Johnson?

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.

Teva Pharmaceutical Initiated at Market Perform at BMO

Teva Pharmaceutical Initiated at Market Perform at BMO

Coverage of Teva Pharmaceutical is initiated at market perform at BMO with a price target of $18.

OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma

OxyContin Maker Purdue Pharma Agrees to $270 Million Settlement With Oklahoma

Most of the settlement money reportedly will go to funding a new center for research, education and treatment of addiction and pain at Oklahoma State University.

Teva Announces Launch Of A Generic Version Of EXJADE® (deferasirox) Tablets For Oral Suspension In The United States

Teva Announces Launch Of A Generic Version Of EXJADE® (deferasirox) Tablets For Oral Suspension In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE ®1 (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot

In this day and age, companies must be 'disruptors' or get left in the dust.

Market Direction, Big Anniversary and a GE Play: Market Recon

Market Direction, Big Anniversary and a GE Play: Market Recon

There is still no news on China trade, so keep your chinstrap buckled and wear your flak jacket.

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector ®1 Patch, 1.

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Pharmaceuticals shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals.

Teva Finalizes Settlement With Federal Trade Commission To Resolve All Outstanding Litigation Between The Parties

Teva Finalizes Settlement With Federal Trade Commission To Resolve All Outstanding Litigation Between The Parties

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a settlement with the Federal Trade Commission (FTC) that will resolve all outstanding litigation between the parties.

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

3 Things to Know at Market Close: Teva, Google and Cisco

3 Things to Know at Market Close: Teva, Google and Cisco

Here's what you need to know on TheStreet.

Teva Pharma Tumbles as Earnings and Outlook Miss Estimates

Teva Pharma Tumbles as Earnings and Outlook Miss Estimates

Teva posts a fourth-quarter earnings miss and issues lower-than-expected guidance for 2019.

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

China trade discussions will continue to be a key driver in Wednesday's market action.

Teva Reports Fourth Quarter And Full Year 2018 Financial Results

Teva Reports Fourth Quarter And Full Year 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2018.

Teva Announces U.S. Launch Of A Generic Version Of Sabril® (Vigabatrin)

Teva Announces U.S. Launch Of A Generic Version Of Sabril® (Vigabatrin)

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Sabril ®1 (vigabatrin) tablets, 500 mg in the US, the first generic version of Sabril ® (vigabatrin) tablets to enter the US market.

Teva Announces Launch Of ALYQ™ (Tadalafil Tablets USP), A Generic Version Of ADCIRCA® In The United States

Teva Announces Launch Of ALYQ™ (Tadalafil Tablets USP), A Generic Version Of ADCIRCA® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of ALYQ™, a generic version of ADCIRCA ®1 (tadalafil) tablets, 20 mg in the U.

Teva Receives Positive Committee For Medicinal Products For Human Use (CHMP) Opinion For AJOVY® (fremanezumab) For The Prophylaxis Of Migraine In Adults

Teva Receives Positive Committee For Medicinal Products For Human Use (CHMP) Opinion For AJOVY® (fremanezumab) For The Prophylaxis Of Migraine In Adults

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for AJOVY ® (fremanezumab)...

Weakness From CAT and NVDA Support Our Repositioning Efforts

The big week of corporate earnings is upon us.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2018 Financial Results At 8 A.m. ET On February 13, 2019

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2018 Financial Results At 8 A.m. ET On February 13, 2019

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2018 financial results on Wednesday, February 13, 2019 at 7:00 a.

Teva To Present At The 37th Annual J.P. Morgan Healthcare Conference

Teva To Present At The 37th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that members of management will present at the 37th Annual J.

Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product

Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that it has resolved its ongoing dispute with Amgen over Teva's generic cinacalcet HCl product.

TheStreet Quant Rating: D (Sell)